Thalidomide-O-C6-NH2 TFA

• CAT Number: I017335
• CAS Number: 1957235-99-2
• Molecular Formula: C₂₁H₂₄F₃N₃O₇
• Molecular Weight: 487.43
• Purity: ≥95%
• Target: Autophagy
• IUPAC Name: 4-(6-aminohexoxy)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C19H23N3O5.C2HF3O2/c20-10-3-1-2-4-11-27-14-7-5-6-12-16(14)19(26)22(18(12)25)13-8-9-15(23)21-17(13)24;3-2(4,5)1(6)7/h5-7,13H,1-4,8-11,20H2,(H,21,23,24);(H,6,7)
• InChIKey: MSWDVCMWKADMFA-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCCCCCCN.C(=O)(C(F)(F)F)O

Thalidomide-O-C6-NH2 TFA（Cat No.:I017335） is a synthetic E3 ligase ligand-linker conjugate that is utilized in the synthesis of the PROTAC dTAG-13. This compound functions as a degrader of FKBP12F36V and BET proteins. The conjugate consists of thalidomide, which acts as the ligand for the target proteins, linked to a C6-NH2 spacer via an O linkage. The addition of the trifluoroacetic acid (TFA) group enhances the compound’s stability and solubility. The resulting PROTAC dTAG-13 demonstrates the ability to induce targeted protein degradation, offering potential applications in drug discovery and therapeutic interventions.

Reference

[1]. Erb MA, et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature. 2017 Mar 9;543(7644):270-274.